---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 0.1 nM epidermal growth factor
effect    : activating
hours     : 1

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148523

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 0.1 nM epidermal growth factor
effect    : activating
hours     : 1.5

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148524

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 0.5 nM epidermal growth factor
effect    : activating
hours     : 1

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148530

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 0.5 nM epidermal growth factor
effect    : activating
hours     : 1.5

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148531

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 1 nM epidermal growth factor
effect    : activating
hours     : 1

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148537

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 1 nM epidermal growth factor
effect    : activating
hours     : 1.5

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148538

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 10 nM epidermal growth factor
effect    : activating
hours     : 1.5

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148544

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 0.1 nM heregulin
effect    : activating
hours     : 1

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148550

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 0.1 nM heregulin
effect    : activating
hours     : 1.5

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148551

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 0.5 nM heregulin
effect    : activating
hours     : 1

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148557

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 0.5 nM heregulin
effect    : activating
hours     : 1.5

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148558

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 1 nM heregulin
effect    : activating
hours     : 1

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148564

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 1 nM heregulin
effect    : activating
hours     : 1.5

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148565

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 10 nM heregulin
effect    : activating
hours     : 1

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148571

---
accession : E-GEOD-6462
platform  : A-AFFY-37
pathway   : EGFR
cells     : MCF-7
treatment : 10 nM heregulin
effect    : activating
hours     : 1.5

control   :
    - GSE6462GSM148516
    - GSE6462GSM148517
perturbed :
    - GSE6462GSM148572
...
